What is the severity of the interaction between tadalafil (phosphodiesterase inhibitor) and sublingual nitroglycerin (nitrate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Severe and Potentially Fatal Interaction Between Tadalafil and Sublingual Nitroglycerin

The interaction between tadalafil and sublingual nitroglycerin is severe and potentially life-threatening, causing profound hypotension that can lead to myocardial infarction and death. This combination is absolutely contraindicated with a mandatory 48-hour waiting period between tadalafil use and nitroglycerin administration 1, 2.

Mechanism of Interaction

The severity of this interaction is based on the pharmacological mechanisms:

  • Tadalafil inhibits phosphodiesterase-5 (PDE5), which normally degrades cyclic guanosine monophosphate (cGMP)
  • Nitrates like sublingual nitroglycerin increase cGMP production
  • When combined, these medications cause synergistic vasodilation, resulting in dramatic and dangerous blood pressure drops 3

Duration of Interaction Risk

The interaction between tadalafil and nitroglycerin follows a specific timeline:

  • Significant interaction persists for 24 hours after tadalafil administration 4
  • At 48 hours post-tadalafil, the interaction is no longer detectable 3, 1
  • This longer duration (compared to 24 hours for sildenafil/vardenafil) is due to tadalafil's longer half-life of 17.5 hours 4

Clinical Evidence of Severity

Research demonstrates the magnitude of this interaction:

  • In controlled studies, co-administration resulted in mean maximal decreases in standing systolic blood pressure that were significantly greater with tadalafil than placebo 5
  • More subjects experienced standing systolic BP <85 mmHg after co-administration of sublingual nitroglycerin with tadalafil compared to placebo 5, 6
  • Cases of myocardial infarction and death have been reported with this combination 3

Management Recommendations

  1. Absolute contraindication: Never administer nitroglycerin to patients who have taken tadalafil within the previous 48 hours 3, 2

  2. Emergency situations: If nitrate administration is deemed medically necessary in a life-threatening situation:

    • At least 48 hours should elapse after the last dose of tadalafil 7
    • Even after 48 hours, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring 7
  3. Patient education: Patients taking PDE5 inhibitors must be clearly informed about:

    • The severity of this interaction
    • The specific waiting period required (48 hours for tadalafil)
    • The need to inform all healthcare providers about tadalafil use 1

Common Pitfalls to Avoid

  • Do not assume shorter waiting periods are safe: Unlike sildenafil/vardenafil (24 hours), tadalafil requires a full 48-hour waiting period before nitrate administration 1, 4

  • Do not rely on patient self-reporting: Specifically ask about PDE5 inhibitor use before administering nitrates

  • Do not attempt dose adjustments: No "safe" dose exists when combining these medications - the interaction is an absolute contraindication 2

This severe drug interaction is consistently recognized across all major cardiovascular guidelines, with no exceptions or situations where co-administration is considered safe 3, 1, 2.

References

Guideline

Drug Interactions and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Time course of the interaction between tadalafil and nitrates.

Journal of the American College of Cardiology, 2003

Research

Cardiovascular effects of tadalafil.

The American journal of cardiology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.